Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
chemistry (298) 298
metallurgy (298) 298
organic chemistry (295) 295
peptides (295) 295
human necessities (243) 243
hygiene (243) 243
medical or veterinary science (243) 243
preparations for medical, dental, or toilet purposes (243) 243
specific therapeutic activity of chemical compounds ormedicinal preparations (153) 153
beer (91) 91
biochemistry (91) 91
enzymology (91) 91
microbiology (91) 91
mutation or genetic engineering (91) 91
spirits (91) 91
vinegar (91) 91
wine (91) 91
compositions thereof (82) 82
culture media (82) 82
microorganisms or enzymes (82) 82
propagating, preserving or maintaining microorganisms (82) 82
fermentation or enzyme-using processes to synthesise a desiredchemical compound or composition or to separate optical isomersfrom a racemic mixture (65) 65
investigating or analysing materials by determining theirchemical or physical properties (60) 60
measuring (60) 60
physics (60) 60
testing (60) 60
humans (17) 17
oncology (13) 13
cd3 complex - immunology (12) 12
index medicus (11) 11
animals (10) 10
mice (10) 10
bispecific antibody (9) 9
combinatorial chemistry (8) 8
libraries, e.g. chemical libraries, in silicolibraries (8) 8
single-chain antibody (8) 8
antibodies, bispecific - immunology (7) 7
antibodies, bispecific - therapeutic use (7) 7
antibodies, bispecific - pharmacokinetics (6) 6
antibodies, bispecific - pharmacology (6) 6
antigens, neoplasm - immunology (6) 6
cancer (6) 6
immunology (6) 6
mice, scid (6) 6
t cells (6) 6
antibodies (5) 5
antibody specificity (5) 5
cell adhesion molecules - immunology (5) 5
cell line, tumor (5) 5
compositions or test papers therefor (5) 5
condition-responsive control in microbiological orenzymological processes (5) 5
epithelial cell adhesion molecule (5) 5
female (5) 5
immunotherapy (5) 5
measuring or testing processes involving enzymes, nucleicacids or microorganisms (5) 5
mice, inbred nod (5) 5
processes of preparing such compositions (5) 5
xenograft model antitumor assays (5) 5
antibodies, bispecific - adverse effects (4) 4
antigens, cd19 - immunology (4) 4
cho cells (4) 4
construct (4) 4
cricetinae (4) 4
cytotoxicity, immunologic - drug effects (4) 4
lymphocyte activation - drug effects (4) 4
monoclonal-antibody (4) 4
neoplasms - immunology (4) 4
t-cells (4) 4
t-lymphocytes - immunology (4) 4
therapy (4) 4
tumor-cells (4) 4
viral antibodies (4) 4
antibodies, bispecific - administration & dosage (3) 3
bite (3) 3
breast-cancer (3) 3
cd3 (3) 3
cd3 complex - metabolism (3) 3
cd8-positive t-lymphocytes - immunology (3) 3
cd8-positive t-lymphocytes - metabolism (3) 3
cell death (3) 3
cytotoxicity (3) 3
derivatives thereof (3) 3
hematology (3) 3
lymphocyte activation (3) 3
lymphoma (3) 3
neoplasms - pathology (3) 3
neoplasms - therapy (3) 3
nucleic acids (3) 3
nucleosides (3) 3
nucleotides (3) 3
ovarian-cancer (3) 3
precursor b-cell lymphoblastic leukemia-lymphoma - therapy (3) 3
single-chain antibodies (3) 3
sugars (3) 3
activation (2) 2
adult (2) 2
analysis (2) 2
antibodies, monoclonal - immunology (2) 2
antibodies, monoclonal - pharmacology (2) 2
antibodies, monoclonal - therapeutic use (2) 2
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (272) 272
French (92) 92
Spanish (46) 46
German (42) 42
Chinese (23) 23
Portuguese (15) 15
Japanese (8) 8
Korean (8) 8
Danish (5) 5
Hungarian (5) 5
Norwegian (5) 5
Croatian (2) 2
Czech (2) 2
Russian (2) 2
Ukrainian (2) 2
Lithuanian (1) 1
Polish (1) 1
Serbian (1) 1
Slovenian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival
by Max S. Topp and Peter Kufer and Nicola Gökbuget and Mariele Goebeler and Matthias Klinger and Svenja Neumann and Heinz-A. Horst and Thorsten Raff and Andreas Viardot and Mathias Schmid and Matthias Stelljes and Markus Schaich and Evelyn Degenhard and Rudolf Köhne-Volland and Monika Brüggemann and Oliver Ottmann and Heike Pfeifer and Thomas Burmeister and Dirk Nagorsen and Margit Schmidt and Ralf Lutterbuese and Carsten Reinhardt and Patrick A. Baeuerle and Michael Kneba and Hermann Einsele and Gert Riethmüller and Dieter Hoelzer and Gerhard Zugmaier and Ralf C. Bargou
Journal of Clinical Oncology, ISSN 0732-183X, 06/2011, Volume 29, Issue 18, pp. 2493 - 2498
Purpose Blinatumomab, a bispecific single-chain antibody targeting the CD19 antigen, is a member of a novel class of antibodies that redirect T cells for... 
ADULT PATIENTS | TRIALS | RELAPSE | PROGNOSTIC-FACTORS | ONCOLOGY | STANDARD-RISK | QUANTIFICATION | CYTOTOXICITY | MRD | CLINICAL-SIGNIFICANCE | TRANSPLANTATION | Antibody Specificity | Immunotherapy - methods | Humans | Middle Aged | Antibodies, Bispecific - pharmacokinetics | Drug Resistance, Neoplasm | Male | Molecular Targeted Therapy | Drug Delivery Systems | Neoplasm, Residual | Young Adult | T-Lymphocytes, Cytotoxic - drug effects | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Agammaglobulinemia - chemically induced | T-Cell Antigen Receptor Specificity - immunology | Aged, 80 and over | T-Cell Antigen Receptor Specificity - drug effects | Adult | Female | B-Lymphocytes - pathology | Antigens, CD19 - immunology | T-Lymphocytes, Cytotoxic - immunology | Antigens, Neoplasm - immunology | Lymphocyte Activation | Kaplan-Meier Estimate | Combined Modality Therapy | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - therapy | Remission Induction | Antibodies, Bispecific - therapeutic use | Cell Lineage | Disease-Free Survival | Antibodies, Bispecific - adverse effects | B-Lymphocytes - immunology | Bone Marrow - pathology | CD3 Complex - immunology | Aged | Lymphopenia - chemically induced
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Selective targeting and potent control of tumor growth using an EphA2/CD3-bispecific single-chain antibody construct
by Hammond, Scott A and Lutterbuese, Ralf and Roff, Shannon and Lutterbuese, Petra and Schlereth, Bernd and Bruckheimer, Elizabeth and Kinch, Michael S and Coats, Steve and Baeuerle, Patrick A and Kufer, Peter and Kiener, Peter A
Cancer Research, ISSN 0008-5472, 04/2007, Volume 67, Issue 8, pp. 3927 - 3935
The EphA2 receptor tyrosine kinase is frequently overexpressed and functionally altered in malignant cells and thus provides opportunities for selective... 
IMMUNODEFICIENT MICE | CANCER THERAPEUTICS | BREAST-CANCER | BISPECIFIC ANTIBODY | EPITHELIAL-CELLS | ONCOLOGY | SQUAMOUS-CELL CARCINOMA | MONOCLONAL-ANTIBODY | PREDICTIVE-VALUE | E-CADHERIN | RECEPTOR TYROSINE KINASE | Antibody Specificity | Cell Growth Processes - immunology | Cricetinae | Immunization, Passive - methods | Cricetulus | Antibodies, Bispecific - pharmacology | Lymphocyte Activation | Humans | Intercellular Junctions - immunology | Mice, SCID | Antibodies, Bispecific - immunology | Epitopes - immunology | Xenograft Model Antitumor Assays | Neoplasms - therapy | Receptor, EphA2 - immunology | Animals | Neoplasms - immunology | CD3 Complex - immunology | Cell Line, Tumor | Mice, Inbred NOD | T-Lymphocytes - immunology | Mice | Neoplasms - pathology | CHO Cells
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Therapeutic window of MuS110, a single-chain antibody construct bispecific for murine EpCAM and murine CD3
by Amann, Maria and Brischwein, Klaus and Lutterbuese, Petra and Parr, Larissa and Petersen, Laetitia and Lorenczewski, Grit and Krinner, Eva and Bruckmeier, Sandra and Lippold, Sandra and Kischel, Roman and Lutterbuese, Ralf and Kufer, Peter and Baeuerle, Patrick A and Schlereth, Bernd
Cancer Research, ISSN 0008-5472, 01/2008, Volume 68, Issue 1, pp. 143 - 151
EpCAM (CD326) is one of the most frequently and highly expressed tumor-associated antigens known and recently has also been found on cancer stem cells derived... 
BREAST-CANCER | TARGET | EP-CAM EXPRESSION | ONCOLOGY | PROGNOSTIC MARKER | OVARIAN-CANCER | ANTITUMOR-ACTIVITY | TUMOR-GROWTH | T-CELLS | CELL ADHESION MOLECULE | ANTIGEN | Lung Neoplasms - drug therapy | Breast Neoplasms - immunology | Humans | Antibodies, Bispecific - pharmacokinetics | Antibodies, Monoclonal - therapeutic use | Cell Adhesion Molecules - immunology | Epithelial Cell Adhesion Molecule | Tissue Distribution | Antigens, Neoplasm - analysis | Antibodies, Monoclonal - immunology | Cricetinae | Antigens, Neoplasm - immunology | Antibodies, Monoclonal - pharmacokinetics | Antibodies, Bispecific - immunology | Breast Neoplasms - drug therapy | Neoplasms - drug therapy | Antibodies, Bispecific - therapeutic use | CD3 Complex - analysis | Lung Neoplasms - immunology | Animals | Neoplasms - immunology | CD3 Complex - immunology | Cell Adhesion Molecules - analysis | Mice | Single-Chain Antibodies | Cytotoxicity, Immunologic
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells
by Ralf Lutterbuese and Tobias Raum and Roman Kischel and Patrick Hoffmann and Susanne Mangold and Benno Rattel and Matthias Friedrich and Oliver Thomas and Grit Lorenczewski and Doris Rau and Evelyne Schaller and Ines Herrmann and Andreas Wolf and Thomas Urbig and Patrick A. Baeuerle and Peter Kufer and Jeffrey V. Ravetch
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 7/2010, Volume 107, Issue 28, pp. 12605 - 12610
Epidermal growth factor receptor (EGFR)-specific monoclonal antibodies predominantly inhibit colorectal cancer (CRC) growth by interfering with receptor... 
Delta cells | HCT116 cells | Epithelial cells | Cell lines | Colorectal cancer | Antibodies | CHO cells | Dosage | Heterologous transplantation | Tumors | Bispecific antibody | Cetuximab | Immunotherapy | Panitumumab | INHIBITION | CONSTRUCTS | MULTIDISCIPLINARY SCIENCES | immunotherapy | bispecific antibody | cetuximab | MICE | panitumumab | TUMOR-GROWTH | Receptor, Epidermal Growth Factor - genetics | Colorectal Neoplasms - genetics | Humans | Risk Factors | Antibodies, Monoclonal | Antibodies, Monoclonal, Humanized | Receptor, Epidermal Growth Factor - metabolism | Mutation - drug effects | Neoplasms - genetics | Colorectal Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Genes, ras - drug effects | Colorectal Neoplasms - pathology | Proto-Oncogene Proteins B-raf | Care and treatment | Cancer cells | Monoclonal antibodies | Genetic aspects | Research | T cells | Health aspects | Cancer | Biological Sciences
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Potent control of tumor growth by CEA/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA
by Lutterbuese, Ralf and Raum, Tobias and Kischel, Roman and Lutterbuese, Petra and Schlereth, Bernd and Schaller, Evelyne and Mangold, Susanne and Rau, Doris and Meier, Petra and Kiener, Peter A and Mulgrew, Kathy and Oberst, Michael D and Hammond, Scott A and Baeuerle, Patrick A and Kufer, Peter
Journal of Immunotherapy, ISSN 1524-9557, 05/2009, Volume 32, Issue 4, pp. 341 - 352
Carcinoembryonic antigen (CEA, CD66e) is a well-characterized tumor-associated antigen that is frequently over-expressed in tumors. Phospholipases release CEA... 
Bispecific antibody | Animal model | CEA | MEDICINE, RESEARCH & EXPERIMENTAL | INFILTRATING LYMPHOCYTES | MONOCLONAL-ANTIBODY | MALIGNANT-MELANOMA | OVARIAN-CANCER | IMMUNOLOGY | COLON-CANCER | LYMPHOMA-CELLS | ONCOLOGY | COLORECTAL-CANCER | T-CELL-ACTIVATION | bispecific antibody | CARCINOEMBRYONIC ANTIGEN | animal model | Recombinant Fusion Proteins - immunology | Cricetinae | Cricetulus | Carcinoembryonic Antigen - blood | Carcinoembryonic Antigen - immunology | Humans | Recombinant Fusion Proteins - therapeutic use | Tetrahydrofolate Dehydrogenase - immunology | Mice, SCID | Antibodies, Bispecific - immunology | Antibodies, Bispecific - therapeutic use | Colorectal Neoplasms - therapy | Animals | Immunotherapy | CD3 Complex - immunology | CD8-Positive T-Lymphocytes - metabolism | Mice | CD8-Positive T-Lymphocytes - immunology | CHO Cells | Tetrahydrofolate Dehydrogenase - genetics
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Regression of human prostate cancer xenografts in mice by AMG 212/BAY2010112, a novel PSMA/CD3-bispecific BiTE antibody cross-reactive with non-human primate antigens
by Friedrich, Matthias and Raum, Tobias and Lutterbuese, Ralf and Voelkel, Markus and Deegen, Petra and Rau, Doris and Kischel, Roman and Hoffmann, Patrick and Brandl, Christian and Schuhmacher, Joachim and Mueller, Peter and Finnern, Ricarda and Fuergut, Melanie and Zopf, Dieter and Slootstra, Jerry W and Baeuerle, Patrick A and Rattel, Benno and Kufer, Peter
Molecular Cancer Therapeutics, ISSN 1535-7163, 12/2012, Volume 11, Issue 12, pp. 2664 - 2673
For treatment of patients with prostate cancer (PCa), we developed a novel T cell-engaging (BiTE) antibody designated AMG 212 or BAY2010112 that is bispecific... 
CELL-ENGAGING ANTIBODY | ACTIVATION | MEMBRANE ANTIGEN | THERAPY | ONCOLOGY | LYSIS | T-CELLS | Humans | Macaca fascicularis | Male | Antibodies, Bispecific - genetics | Prostatic Neoplasms - immunology | Prostatic Neoplasms - therapy | CD3 Complex - genetics | Transfection | Female | CHO Cells | Glutamate Carboxypeptidase II - immunology | Prostatic Neoplasms - pathology | Cricetinae | Immunization, Passive - methods | Antibodies, Bispecific - pharmacology | Mice, SCID | Antibodies, Bispecific - immunology | Haplorhini | Cross Reactions | Xenograft Model Antitumor Assays | Animals | CD3 Complex - immunology | Mice, Inbred NOD | Mice | Mice, Inbred BALB C | Antigens, Surface - immunology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text MT110: A novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors
by Brischwein, Klaus and Schlereth, Bernd and Guller, Benjamin and Steiger, Carola and Wolf, Andreas and Lutterbuese, Ralf and Offner, Sonja and Locher, Mathias and Urbig, Thomas and Raum, Tobias and Kleindienst, Petra and Wimberger, Pauline and Kimmig, Rainer and Fichtner, Iduna and Kufer, Peter and Hofmeister, Robert and da Silva, Antonio J and Baeuerle, Patrick A
Molecular Immunology, ISSN 0161-5890, 2006, Volume 43, Issue 8, pp. 1129 - 1143
We have developed a novel single-chain Ep-CAM-/CD3-bispecific single-chain antibody construct designated MT110. MT110 redirected unstimulated human peripheral... 
Single-chain antibody | Tumor | Ep-CAM | CD3 | BiTE | Xenograft model | NATURAL-KILLER-CELLS | BIOCHEMISTRY & MOLECULAR BIOLOGY | MONOCLONAL-ANTIBODY | COLORECTAL-CARCINOMA | OVARIAN-CANCER | IMMUNOLOGY | VERSUS-HOST-DISEASE | single-chain antibody | BREAST-CANCER | xenograft model | EP-CAM-/CD3-BISPECIFIC ANTIBODY | tumor | STEM-CELL TRANSPLANTATION | T-CELLS | Antibody Specificity | Humans | CD4-Positive T-Lymphocytes - metabolism | Antibodies, Monoclonal - therapeutic use | Mice, SCID | Antibodies, Bispecific - immunology | CD3 Complex - metabolism | Neoplasms - drug therapy | Dose-Response Relationship, Drug | Recombinant Proteins - isolation & purification | Antibodies, Bispecific - therapeutic use | Lymphocyte Activation - immunology | Animals | CD8-Positive T-Lymphocytes - metabolism | Cell Line, Tumor | Mice, Inbred NOD | Antigens, CD19 - metabolism | Mice | Kinetics | Single-Chain Antibodies | Neoplasms - pathology | Antibodies, Monoclonal - immunology | Cytotoxicity, Immunologic | Disease Models, Animal | Viral antibodies | Colon cancer | Analysis | Antibodies | Metastasis | Biological response modifiers | T cells | Cancer | Interferon gamma
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Eradication of tumors from a human colon cancer cell line and from ovarian cancer metastases in immunodeficient mice by a single-chain Ep-CAM-/CD3- bispecific antibody construct
by Schlereth, Bernd and Fichtner, Iduna and Lorenczewski, Grit and Kleindienst, Petra and Brischwein, Klaus and Da Silva, Antonio and Kufer, Peter and Lutterbuese, Ralf and Junghahn, Ilse and Kasimir-Bauer, Sabine and Wimberger, Pauline and Kimmig, Rainer and Baeuerle, Patrick A
Cancer Research, ISSN 0008-5472, 04/2005, Volume 65, Issue 7, pp. 2882 - 2889
Bispecific T-cell engager (BiTE) are a class of bispecific single-chain antibodies that can very effectively redirect cytotoxic T cells for killing of tumor... 
BISPECIFIC ANTIBODY | THERAPY | ONCOLOGY | INFILTRATING LYMPHOCYTES | HUMAN MONOCLONAL-ANTIBODY | VACCINATION | MT201 | T-LYMPHOCYTES | Antibody Specificity | Humans | Ovarian Neoplasms - pathology | Antibodies, Bispecific - pharmacokinetics | Cell Adhesion Molecules - immunology | Epithelial Cell Adhesion Molecule | Colonic Neoplasms - immunology | Female | Peritoneal Neoplasms - immunology | Peritoneal Neoplasms - secondary | Colonic Neoplasms - therapy | Antibodies, Bispecific - pharmacology | Antigens, Neoplasm - immunology | Mice, Inbred C57BL | Mice, SCID | Antibodies, Bispecific - immunology | Xenograft Model Antitumor Assays | Animals | CD3 Complex - immunology | Cell Line, Tumor | Ovarian Neoplasms - therapy | Mice, Inbred NOD | Mice | Peritoneal Neoplasms - therapy | Ovarian Neoplasms - immunology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Abstract 3630: Preclinical evaluation of a BiTE® antibody construct with extended half-life that targets the tumor differentiation marker mesothelin
by Sternjak, Alexander and Lee, Fei and Wahl, Joachim and Rock, Dan and Thomas, Oliver and Stienen, Sabine and Lutterbuese, Ralf and Hoffmann, Patrick and Raum, Tobias and Kufer, Peter and Rattel, Benno and Coxon, Angela and Friedrich, Matthias and Bailis, Julie
Cancer Research, ISSN 0008-5472, 07/2017, Volume 77, Issue 13 Supplement, pp. 3630 - 3630
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Combination of rituximab with blinatumomab (MT103/MEDI-538), a T cell-engaging CD19-/CD3-bispecific antibody, for highly efficient lysis of human B lymphoma cells
by d’Argouges, Sandrine and Wissing, Sandra and Brandl, Christian and Prang, Nadja and Lutterbuese, Ralf and Kozhich, Alex and Suzich, JoAnn and Locher, Mathias and Kiener, Peter and Kufer, Peter and Hofmeister, Robert and Baeuerle, Patrick A and Bargou, Ralf C
Leukemia Research, ISSN 0145-2126, 2008, Volume 33, Issue 3, pp. 465 - 473
Abstract We have compared the cytotoxic activity of rituximab with that of blinatumomab (MT103/MEDI-538), a single-chain CD19-/CD3-bispecific antibody engaging... 
Hematology, Oncology and Palliative Medicine | Rituximab | Antibody therapy | Natural killer cells | T cells | Blinatumomab | Combination | CD20 | APOPTOSIS | CONSTRUCT | SINGLE-CHAIN ANTIBODY | FOLLICULAR LYMPHOMA | ANTI-CD20 MONOCLONAL-ANTIBODY | INHIBITION | ONCOLOGY | IN-VIVO | CHRONIC LYMPHOCYTIC-LEUKEMIA | HEMATOLOGY | CYTOTOXICITY | Caspase 7 - metabolism | Antibodies, Monoclonal, Murine-Derived | Antibodies, Bispecific - pharmacology | Antibodies, Monoclonal - pharmacology | Granzymes | Humans | Caspase 3 - metabolism | Antineoplastic Combined Chemotherapy Protocols | Drug Synergism | CD3 Complex - immunology | Lymphoma, B-Cell - pathology | Tumor Cells, Cultured | Cytotoxicity, Immunologic - drug effects | Antigens, CD19 - immunology | Lymphoma, B-Cell - drug therapy | Cell death | Lymphomas | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Abstract 585: Assessing ENPP3 as a renal cancer target for bispecific T-cell engager (BiTE) therapy
by Nolan-Stevaux, Olivier and Fajardo, Flordeliza and Liu, Lily and Coberly, Suzanne and McElroy, Patricia and Nazarian, Aaron and Bott, Franziska and Nahrwold, Elisabeth and Raum, Tobias and Kischel, Roman and Lutterbuese, Ralf and Hoffmann, Patrick and Kufer, Peter
Cancer Research, ISSN 0008-5472, 07/2016, Volume 76, Issue 14 Supplement, pp. 585 - 585
BiTE therapeutics are single chain antibody constructs harboring two binding moieties: one directed at a tumor associated antigen and one directed at the CD3e... 
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Antitumor activity of an EpCAM/CD3-bispecific BiTE antibody during long-term treatment of mice in the absence of t-cell anergy and sustained cytokine release
by Amann, Maria and DÁrgouges, Sandrine and Lorenczewski, Grit and Brischwein, Klaus and Kischel, Roman and Lutterbuese, Ralf and Mangold, Susanne and Rau, Doris and Volkland, Jörg and Pflanz, Stefan and Raum, Tobias and Münz, Markus and Kufer, Peter and Schlereth, Bernd and Baeuerle, Patrick A and Friedrich, Matthias
Journal of Immunotherapy, ISSN 1524-9557, 06/2009, Volume 32, Issue 5, pp. 452 - 464
muS110 is a BiTE antibody bispecific for marine EpCAM (CD326) and marine CD3. MT110, its human-specific analog, is in a clinical phase 1 trial for treatment of... 
Anergy | EpCAM | MT110 | Bispecific antibody | Glucocorticoid | IL-10 | CD3 | Cytotoxic T cell | Therapeutic window | Cytokine release | MuS110 | Mouse model | Cancer | MEDICINE, RESEARCH & EXPERIMENTAL | cytokine release | glucocorticoid | CONSTRUCT | mouse model | ANTI-CD3 MONOCLONAL-ANTIBODY | MURINE CD3 | SINGLE-CHAIN ANTIBODY | TUMOR-CELLS | IMMUNOLOGY | CANCER-THERAPY | anergy | cytotoxic T cell | muS110 | ONCOLOGY | therapeutic window | INTERLEUKIN-10 PRODUCTION | bispecific antibody | cancer | Mammary Neoplasms, Experimental - immunology | Neoplasm Transplantation | Cell Adhesion Molecules - genetics | Humans | Cell Adhesion Molecules - immunology | Epithelial Cell Adhesion Molecule | CD3 Complex - genetics | Clonal Anergy - drug effects | T-Lymphocytes - metabolism | Time Factors | T-Lymphocytes - drug effects | Antibodies, Bispecific - administration & dosage | Immunotherapy | Mammary Neoplasms, Experimental - pathology | Protein Engineering | Antigens, Neoplasm - metabolism | Female | T-Lymphocytes - pathology | Antigens, Neoplasm - genetics | Cytokines - metabolism | Antigens, Neoplasm - immunology | Immunologic Factors - administration & dosage | CD3 Complex - metabolism | Cell Adhesion Molecules - metabolism | Mammary Neoplasms, Experimental - therapy | Animals | Antibodies, Bispecific - adverse effects | Lymphocyte Activation - drug effects | CD3 Complex - immunology | T-Lymphocytes - immunology | Cell Proliferation - drug effects | Immunologic Factors - adverse effects | Mice | Mice, Inbred BALB C | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Abstract 55: Generation of half-life extended anti-CD33 BiTE® antibody constructs compatible with once-weekly dosing
by Arvedson, Tara L and Balazs, Mercedesz and Bogner, Pamela and Black, Kurt and Graham, Kevin and Henn, Anja and Friedrich, Matthias and Hoffmann, Patrick and Kischel, Roman and Kufer, Peter and Lutterbuese, Ralf and Muenz, Markus and Raum, Tobias and Rattel, Benno and Rex, Karen and Rock, Dan and Thomas, Oliver and Wahl, Joachim and Wolf, Andreas and Coxon, Angela
Cancer Research, ISSN 0008-5472, 07/2017, Volume 77, Issue 13 Supplement, pp. 55 - 55
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Abstract 3523: Preclinical characterization of MT114, a novel CD33/CD3-bispecific BiTE antibody for the treatment of acute myeloid leukemia (AML)
by Henn, Anja and Friedrich, Matthias and Kischel, Roman and Lutterbuese, Ralf and Schneider, Katja and Mueller, Peter and Baeuerle, Patrick A and Raum, Tobias and Kufer, Peter and Rattel, Benno
Cancer Research, ISSN 0008-5472, 04/2012, Volume 72, Issue 8 Supplement, pp. 3523 - 3523
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Selective Targeting and Potent Control of Tumor Growth Using an EphA2/CD3-Bispecific Single-Chain Antibody Construct
by Hammond, Scott A and Lutterbuese, Ralf and Roff, Shannon and Lutterbuese, Petra and Schlereth, Bernd and Bruckheimer, Elizabeth and Kinch, Michael S and Coats, Steve and Baeuerle, Patrick A and Kufer, Peter and Kiener, Peter A
Cancer Research, ISSN 0008-5472, 04/2007, Volume 67, Issue 8, pp. 3927 - 3935
The EphA2 receptor tyrosine kinase is frequently overexpressed and functionally altered in malignant cells and thus provides opportunities for selective... 
Journal Article
Details down arrow
16. Therapeutic Window of MuS110, a Single-Chain Antibody Construct Bispecific for Murine EpCAM and Murine CD3
by Amann, Maria and Brischwein, Klaus and Lutterbuese, Petra and Parr, Larissa and Petersen, Laetitia and Lorenczewski, Grit and Krinner, Eva and Bruckmeier, Sandra and Lippold, Sandra and Kischel, Roman and Lutterbuese, Ralf and Kufer, Peter and Baeuerle, Patrick A and Schlereth, Bernd
Cancer Research, ISSN 0008-5472, 01/2008, Volume 68, Issue 1, pp. 143 - 151
EpCAM (CD326) is one of the most frequently and highly expressed tumor-associated antigens known and recently has also been found on cancer stem cells derived... 
Journal Article
Details down arrow
17. Full Text Abstract 4561: Preclinical characterization of MT112/BAY 2010112, a novel PSMA/CD3-bispecific BiTE antibody for the treatment of prostate cancer
by Lutterbuese, Ralf and Friedrich, Matthias and Kischel, Roman and Rau, Doris and Hoffmann, Patrick and Ebert, Evelyn and Zopf, Dieter and Finnern, Ricarda and Mueller, Peter and Baeuerle, Patrick A and Wolf, Andreas and Rattel, Benno and Raum, Tobias and Kufer, Peter
Cancer Research, ISSN 0008-5472, 04/2011, Volume 71, Issue 8 Supplement, pp. 4561 - 4561
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
18. T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells
by Ralf Lutterbuese and Tobias Raum and Roman Kischel and Patrick Hoffmann and Susanne Mangold and Benno Rattel and Matthias Friedrich and Oliver Thomas and Grit Lorenczewski and Doris Rau and Evelyne Schaller and Ines Herrmann and Andreas Wolf and Thomas Urbig and Patrick A Baeuerle and Peter Kufer
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 07/2010, Volume 107, Issue 28, p. 12605
  Epidermal growth factor receptor (EGFR)-specific monoclonal antibodies predominantly inhibit colorectal cancer (CRC) growth by interfering with receptor... 
Colorectal cancer | Oncology | T cell receptors | Mutation | Binding sites | Immune system
Journal Article
Details down arrow
19. Full Text Abstract 2429: Evidence of a therapeutic window with a T cell-engaging BiTE antibody based on monoclonal antibody cetuximab
by Lutterbuese, Ralf and Thomas, Oliver and Raum, Tobias and Kischel, Roman and Hoffmann, Patrick and Friedrich, Matthias and Lorenczweski, Grit and Wolf, Andreas and Urbig, Thomas and Schaller, Evelyn and Rau, Doris and Mangold, Susanne and Baeuerle, Patrick A and Kufer, Peter and Rattel, Benno
Cancer Research, ISSN 0008-5472, 04/2010, Volume 70, Issue 8 Supplement, pp. 2429 - 2429
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
20. Full Text Potent inhibition of local and disseminated tumor growth in immunocompetent mouse models by a bispecific antibody construct specific for Murine CD3
by Schlereth, Bernd and Schlereth, Bernd and Kleindienst, Petra and Kleindienst, Petra and Fichtner, Iduna and Fichtner, Iduna and Lorenczewski, Grit and Lorenczewski, Grit and Brischwein, Klaus and Brischwein, Klaus and Lippold, Sandra and Lippold, Sandra and Silva, Antonio da and Silva, Antonio da and Locher, Mathias and Locher, Mathias and Kischel, Roman and Kischel, Roman and Lutterbüse, Ralf and Lutterbüse, Ralf and Kufer, Peter and Kufer, Peter and Baeuerle, Patrick A and Baeuerle, Patrick A
Cancer Immunology, Immunotherapy, ISSN 0340-7004, 7/2006, Volume 55, Issue 7, pp. 785 - 796
Bispecific single-chain antibody constructs specific for human CD3 have been extensively studied for antitumor activity in human xenograft models using severe... 
Biomedicine | Immunology | Ep-CAM | Tumor immunity | Oncology | Cancer Research | T lymphocyte | Bispecific antibody | Xenograft model | SINGLE-CHAIN ANTIBODY | tumor immunity | MONOCLONAL-ANTIBODY | IMMUNOLOGY | CELL ADHESION MOLECULE | B-CELLS | xenograft model | ONCOLOGY | IN-VIVO | bispecific antibody | LYMPHOMA | CYTOTOXICITY | T-CELLS | X ANTI-CD3 | Recombinant Fusion Proteins - immunology | Antibody Specificity | Neoplasm Transplantation | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - pathology | Dose-Response Relationship, Immunologic | Humans | Antibodies, Bispecific - pharmacokinetics | Cell Line, Tumor - transplantation | Cell Adhesion Molecules - immunology | Epithelial Cell Adhesion Molecule | Melanoma, Experimental - immunology | Lung Neoplasms - secondary | Immunotherapy | Subcutaneous Tissue | Immunocompetence | Antigens, Neoplasm - immunology | Melanoma, Experimental - therapy | Mice, Inbred C57BL | Lung Neoplasms - therapy | Mice, SCID | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - therapy | Antibodies, Bispecific - immunology | Xenograft Model Antitumor Assays | Antibodies, Bispecific - therapeutic use | Animals | CD3 Complex - immunology | Mice, Inbred NOD | Mice | Drug Screening Assays, Antitumor | Viral antibodies | Antibodies | Models | Lung cancer | Tumors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.